Glioblastoma (GBM), the grade IV glioma, is among the most lethal of human malignancies, distinguished by prominent vascularity. GBM is the most aggressive primary brain tumor with a current median survival of about 14-16 months, largely due to its high resistance to conventional cytotoxic therapies. Overgrown vasculature characterizes the tumor microenvironment that fuels GBM progression and induces vascular niche-mediated therapeutic resistance. However, current anti-vascular therapy that primarily targets pro- angiogenic factors including VEGF, albeit initially groundbreaking, has encountered major difficulties and failures in treating most malignant solid tumors including GBM, likely due to insufficient eradication or functional inhibition of tumor-associated endothelial cells (ECs). Our recent studies suggest that EC plasticity by genetic reprogramming is a driving force that induces EC resistance to anti-angiogenic and cytotoxic treatments. Here, our preliminary study by single-cell transcriptome analysis of tumor-associated ECs reveals that ECs acquire mesenchymal and stemness-like gene signature in a genetically engineered mouse GBM model. Utilizing human specimens and EC lineage-tracing systems, our studies reveal robust treatment resistance in GBM-associated ECs. Our in vitro and in vivo data suggest that genetic reprogramming into mesenchymal stem cell (MSC)-like cells induces EC chemoresistance through Wnt activation in GBM. Therefore, we hypothesize that mesenchymal and stemness-like genetic reprogramming in tumor ECs induces therapy resistance in GBM. We will test this hypothesis by pursuing the following aims: 1) Define the molecular mechanism underlying EC plasticity and treatment resistance with a focus on Wnt activation; 2) Determine the in vivo role of c-Met/Wnt-mediated EC plasticity in tumor progression; and 3) Test experimental therapy that combines EC plasticity inhibition with radio/chemotherapy or anti-angiogenic therapy in orthotopic mouse GBM models. Successful completion of the proposed work will provide novel insights into tumor microenvironment-dependent treatment resistance, and may lead to development of a new therapeutic strategy by targeting endothelial plasticity in cancer.

Public Health Relevance

Glioblastoma (GBM) is among the most lethal of human malignancies with a current median survival of about 14 months. The goals of this project are to understand the mechanism of tumor therapy resistance and to develop new therapy for treating GBM.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
2R01NS094533-06A1
Application #
10116668
Study Section
Tumor Microenvironment Study Section (TME)
Program Officer
Fountain, Jane W
Project Start
2015-09-30
Project End
2025-11-30
Budget Start
2020-12-15
Budget End
2021-11-30
Support Year
6
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Wang, Yanling; Xu, Haineng; Liu, Tianrun et al. (2018) Temporal DNA-PK activation drives genomic instability and therapy resistance in glioma stem cells. JCI Insight 3:
Yuan, Jiao; Hu, Zhongyi; Mahal, Brandon A et al. (2018) Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers. Cancer Cell 34:549-560.e9
Liu, Tianrun; Ma, Wenjuan; Xu, Haineng et al. (2018) PDGF-mediated mesenchymal transformation renders endothelial resistance to anti-VEGF treatment in glioblastoma. Nat Commun 9:3439
Wang, Qirui; He, Zhenqiang; Huang, Menggui et al. (2018) Vascular niche IL-6 induces alternative macrophage activation in glioblastoma through HIF-2?. Nat Commun 9:559
Lin, Xiaojuan; Shen, Jianfeng; Dan Peng et al. (2018) RNA-binding protein LIN28B inhibits apoptosis through regulation of the AKT2/FOXO3A/BIM axis in ovarian cancer cells. Signal Transduct Target Ther 3:23
Yang, Lu; Zhang, Youyou; Shan, Weiwei et al. (2017) Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition. Sci Transl Med 9:
Zhang, Youyou; He, Qun; Hu, Zhongyi et al. (2016) Long noncoding RNA LINP1 regulates repair of DNA double-strand breaks in triple-negative breast cancer. Nat Struct Mol Biol 23:522-30
Huang, Menggui; Liu, Tianrun; Ma, Peihong et al. (2016) c-Met-mediated endothelial plasticity drives aberrant vascularization and chemoresistance in glioblastoma. J Clin Invest 126:1801-14